Dedicated to cell & gene therapies development and manufacturing


The world’s largest dedicated cell and gene therapies (CGT) manufacturing facility at its opening in 2018, our Houston site is now approved for commercial manufacture.
 
This 300,000-square-foot facility is our US centre-of-excellence for process development (PD) activities of cell therapies, gene therapies and viral vectors. The site also houses large Research & Development laboratories dedicated to developing future cell and gene therapies innovations and technologies. In 2021, the site was officially approved for commercial production of a gene therapy by the FDA. 

Many of our customers start process development activities in the PD laboratories, before naturally transitioning to the cGMP manufacturing floor into one of our cGMP suites located under the same roof.  We purposefully built the facility with future capacity in mind, to enable scale-up manufacturing in line with our customer’s needs, so that, together, we can make more therapies available to patients.


300k
square feet
400+
employees
2018
year established

Tailored solutions for each step


  • Flexible: Our flexible suite set up can be readily adapted based on your individual processes.
  • Single use: We employ single-use disposables in all of our manufacturing processes. Additionally, we have multiple parallel GMP viral vector trains and cell therapy suites that have independent air handling units, ensuring maintenance can be performed without affecting other suites. 
  • Ability to serve a large number of patients: Fully expanded, our footprint is capable of supporting more than 200 clinical and commercial viral vector cGMP batches annually. 
  • Supporting a wide variety of cell and viral vector types: The full range of services provided at this site can support a wide selection of cell and virus types, such as T-cells, dendritic cells, pluripotent stem cells (PSCs) and mesenchymal stem cells (MSCs) as well as adenoviral, adeno-associated virus (AAV), lentiviral and other viral vectors.

A full range of services under one roof


We offer process development and bioassay services in addition to clinical and commercial manufacturing for cell and gene therapies, including viral vector production. We support customers at all stages of development, from process development to first-in-human trials and commercial production.

(Re)Live the April 10th 2018 Grand Opening Ceremony